Chris Wilkins

Learn More
BACKGROUND Benzylpiperazine (BZP) is the psychoactive ingredient in a range of 'legal highs' sold worldwide. BZP was prohibited in New Zealand in 2008. AIM To investigate the impact of the prohibition of BZP legal highs on the prevalence of BZP, replacement legal highs and other drugs. METHODS A population survey of BZP and other drugs was conducted in(More)
In this Harm Reduction Digest Sheridan, Butler, Wilkins and Russell address the emergent phenomenon of so-called 'legal party pills' which have become a significant drug issue in New Zealand and elsewhere. Although banned in a number of countries, they are currently legally available in New Zealand where they are marketed as 'safe' alternatives' to(More)
INTRODUCTION AND AIMS A large legal market for party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) developed in New Zealand after 2004. The use of these party pills has been associated with adverse health effects. The purpose of this paper was to assess a general population sample of party pill users to investigate the(More)
This paper aims to set out some of the policy and public health issues raised by the appearance of a wide range of emergent psychoactive substances of diverse origin, effect and risk profile (commonly referred to as 'legal highs'). It will start by considering what is meant by the term 'legal highs' and consider the historical context that has framed their(More)
AIM To track trends in drug use in the New Zealand population over the past 8 years. METHOD National household surveys of drug use were conducted in New Zealand in 1998, 2001, 2003,and 2006 using the same Computer Assisted Telephone Interview (CATI) methodology. The age ranges of the random digit dial (RDD) samples from each survey wave were truncated to(More)
BACKGROUND In mid-July 2013, New Zealand passed the Psychoactive Substances Act (PSA), which allowed 'low risk' psychoactive products ('legal highs') to be approved for legal sale. In early May 2014, following public protest, the Psychoactive Substances Amendment Act (PSAA) was passed banning animal testing of psychoactive products, potentially making the(More)
BACKGROUND There have been no changes to the statutory penalties for cannabis use in New Zealand for over 35 years and this has attracted some criticism. However, statutory penalties often provide a poor picture of the actual criminal justice outcomes for minor drug offending. AIM To examine criminal justice outcomes for cannabis use offences in New(More)
BACKGROUND 'Party' pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) were sold legally in New Zealand until early 2008. Prospective studies of hospital emergency department admissions appeared to suggest that the harm from party pills was greater among South Island than North Island users. The party pill industry(More)
BACKGROUND Legal highs containing benzylpiperazine (BZP) were widely sold in New Zealand until BZP was prohibited in 2008. We examined the impact the prohibition had on the availability and price of BZP over following years. METHODS Two national population surveys of BZP use were conducted in 2006 and 2009. Four annual targeted surveys of frequent drug(More)
BACKGROUND New Zealand has recently attempted to address the underlying drivers of the escalating new psychoactive substances (NPS) ('legal highs') problem by establishing the world's first pre-market approval regulatory regime for NPS. NPS products which can be shown with clinical trial data to pose a 'low risk' of harm will be approved for legal(More)